A new analysis of breast tumors, before and after hormone-reduction therapy, reveals the extreme genetic complexity of these tumors and the variety of responses that are possible to estrogen-deprivation treatments. The findings also suggest that analyzing a single sample of the breast tumor is insufficient for understanding how a patient should best be treated.
– Washington University in St. Louis
Nature Communications Embargo expired on 09-Aug-2016 at 05:00 ET
For patients with the most common type of noninvasive breast cancer, routine testing for estrogen and progesterone receptors in tissue taken at the first "needle" biopsy is both unnecessary and wasteful, according to results of a study led by Johns Hopkins pathologists.
– Johns Hopkins Medicine
The American Journal of Surgical Pathology
Wistar scientists have identified a novel mechanism that selectively operates in hypoxic tumors to enable tumor cells to thrive and continue to proliferate despite a low oxygen environment. Dario C. Altieri, M.D., Wistar’s President and CEO and lead author of the study, and colleagues showed how the activation of this pathway leads to an unfavorable prognosis for patients with gliomas – a type of brain tumor – and how the pathway could be a valuable therapeutic target in cancer.
– Wistar Institute
Cancer Cell; DOI Number: 10.1016/j.ccell.2016.07.004; P01 CA140043, R01 CA78810, CA190027, R01 CA089720, F32CA177018, W81XWH-13-1-0193, 2014-1148, HEALTH-2012-INNOVATION-1, GA305311,... Embargo expired on 08-Aug-2016 at 12:00 ET
Men with testicular cancer who were uninsured or on Medicaid had a higher risk of death from what is normally a curable disease than insured patients, a new study by Dana-Farber Cancer Institute researchers found.
– Dana-Farber Cancer Institute
Cancer Embargo expired on 08-Aug-2016 at 00:05 ET
In the search for new ways to attack recurrent prostate cancer, researchers at Duke Health report that a novel compound appears to have a unique way of blocking testosterone from fueling the tumors in mice.
– Duke Health
Nature Chemical Biology; W81XWH-10-1-0179; PHS5R01DK015556; T32ES007326; 1 F30 DK083899; W81XWH-13-1-0196 Embargo expired on 08-Aug-2016 at 11:00 ET
Click here to go directly to the Cancer News Source
Men with very high-risk prostate cancer, who are treated at hospitals with a high proportion of administered radical local treatment (radiotherapy or prostatectomy), only have half of the mortality risk of men who are treated at hospitals with the lowest proportion. This is according to a new study conducted by researchers at Umeå University in Sweden and published in European Urology.
– Umea University
Though the health systems in Brazil, Colombia, El Salvador, Jamaica, Mexico and Panama have considerable strengths, citizens still reported gaps in the way primary care is organized, financed and delivered in those countries. Those who had better experiences were less likely to say that their health system needed major reforms.
– University of California, Los Angeles (UCLA), Health Sciences
Wistar scientists have identified a marker that distinguishes PMN-MDSCs from neutrophils in the blood of patients with a variety of cancers.
– Wistar Institute
Science Immunology; DOI Number: 10.1126/sciimmunol.aaf8943; CA084488, CA100062, P01 CA 098101, RP-10-033-01-CCE Embargo expired on 05-Aug-2016 at 14:00 ET
In a retrospective study analyzing patients' medical records, researchers at Brigham and Women's Hospital found that patients' race significantly affected their longevity by increasing the likelihood of death after receiving androgen deprivation therapy (ADT). ADT was used to reduce the size of the prostate to make a patient eligible for prostate brachytherapy. These findings are published in the August 4, 2016 issue of Cancer.
– Brigham and Women’s Hospital
Lymphoma is a cancer that affects lymphocytes, a type of white blood cell. The disease originates in a lymphoid organ (lymph node, spleen, or bone marrow) before spreading through the blood to infiltrate not only other lymphoid organs but also other tissues. Every year, nearly 2,000 people in Switzerland are diagnosed with lymphoma, a disease that can be very aggressive, resisting standard treatments with chemotherapeutic drugs. Today, researchers at the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG), Switerland, give a new hope to patients. Their innovative approach consists in using an antibody able to neutralize a specific protein to block the migration of lymphoma cells, thus preventing the disease from developing. This still experimental immunotherapeutic strategy paves the way for new treatments against lymphoma. The results can be read in the Journal of Leukocyte Biology.
– Université de Genève (University of Geneva)
Journal of Leukocyte Biology
Galectin-3, a well-known lectin protein that binds with sugars, could have a number of interactions with other sugar-seeking proteins, which may complicate the biological processes that drive cancer growth, neural growth and white blood cell activities.
– Michigan Technological University
A study led by Professor Daniel Tenen, Director of the Cancer Science Institute of Singapore at the National University of Singapore, found that inhibiting a protein called BMI1 could inhibit the development of lung cancer.
– National University of Singapore
Science Translational Medicine
Brooklyn has always been home to Josef A. Shehebar, MD, FACS, FASCRS. When he was recruited recently by NYU Lutheran to expand and grow the Division of Colon and Rectal Surgery, Dr. Shehebar couldn't pass up the opportunity to work in the borough where his roots are firmly planted.
– NYU Langone Medical Center
Robert Legaspi was 9 years old when he was first diagnosed with acute lymphoblastic leukemia (ALL). This year, at age 27, his leukemia returned for the fourth time. This time was different, though — on May 20, 2016, Legaspi became the first patient in San Diego to receive a new type of immunotherapy, known as CAR T-cell therapy, as part of a Phase I/II clinical trial at Moores Cancer Center at UC San Diego Health.
– University of California San Diego Health Sciences
ROCHESTER, Minn. — A team of Mayo Clinic researchers has identified evidence of bacteria in sterilely-obtained breast tissue and found differences between women with and without breast cancer. The findings are published in the Aug. 3 issue of Scientific Reports.
– Mayo Clinic Embargo expired on 03-Aug-2016 at 05:00 ET
Text-mining tool developed at CU Cancer Center and published today in Bioinformatics helps researchers map connections between genes, proteins, drugs, diseases.
– University of Colorado Cancer Center
Bioinformatics; NIH 50CA058187; NIH P30CA046934
Investigators from Brigham and Women's Hospital have found that "non-functional" adrenal tumors can increase a person's risk of developing type 2 diabetes. Benign adrenal tumors that don't appear to secrete hormones are labeled as "non-functional" and are currently considered by physicians to pose no health risks, but these new results challenge that assumption.
– Brigham and Women’s Hospital
Annals of Internal Medicine
Lung cancer is the most common cause of cancer deaths, accounting for about a third of all tumor-related deaths. Adenocarcinomas, a non-small cell lung cancer (NSCLC), account for about 40 percent of cancer diagnoses, but few treatments are available for the disease. A team of investigators led by Elena Levantini, PhD, a research associate in Hematology-Oncology at Beth Israel Deaconess Medical Center (BIDMC), instructor of medicine at Harvard Medical School and a member of the Harvard Stem Cell Institute, have identified a subtype of human adenocarcinoma. The research could help determine which individuals are at greatest risk of developing lung tumors that may be amenable to a new therapy to inhibit their progression.
– Beth Israel Deaconess Medical Center
FAMRI YCSA 072165; 5P30 CA006516; Science Translational Medicine; NIH/NCI P50 CA90578; FAMRI YCSA 052409 ; FAMRI CIA 103063; FIJC-10; NCI T32/K12/R25 ...
A new study suggests that tweaking metabolic steps in combination with checkpoint blockade drugs may improve some cancer therapies.
– Perelman School of Medicine at the University of Pennsylvania
AI105343, AI082630, AI095608, AI112521, AI115712, AI117718, AI108545, NIHAI2010085, P50CA121973
Cancer immunotherapy drugs that block the inhibitory PD-1 pathway have shown success in clinical trials and are now FDA-approved for melanoma, lung cancer and bladder cancer. Yet many patients' tumors do not respond to these drugs.
– Emory Health Sciences
Cancer cells need oxygen to survive, as do most other life forms, but scientists had never tracked their search for oxygen in their early growth stages until now -- a step toward a deeper understanding of one way cancer spreads that could help treat the disease.
– Johns Hopkins University
PNAS Early Edition, Aug-2016; CA153952; CA158301; 1054415
Expanding the leadership of its five core research programs, Rutgers Cancer Institute of New Jersey has announced new roles for research members serving as co-program leaders, spanning across three divisions: basic science, clinical science, and population science.
– Rutgers Cancer Institute of New Jersey
Roy Jensen, MD, director of The University of Kansas Cancer Center, will be the new Vice President/President-elect of the Association of American Cancer Institutes.
– Association of American Cancer Institutes (AACI)
Media are encouraged to register to attend the second annual International Cancer Immunotherapy Conference organized by the Cancer Research Institute, Association for Cancer Immunotherapy, European Academy of Tumor Immunology, and the American Association for Cancer Research.
– Cancer Research Institute
The American Society for Radiation Oncology (ASTRO) has selected four early career scientists to receive a total of $275,000 in research awards, including one winner of the ASTRO Junior Faculty Career Research Training Award and three recipients of ASTRO Resident/Fellows in Radiation Oncology Research Seed Grants.
– American Society for Radiation Oncology (ASTRO)